Chloe Simmons
Primary Care · Monteagle, TNNPI 1952953051
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 176 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 28 manufacturers, the largest accounting for just 19.2% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2021 at $1,541 and has fallen 93.7% since, to $96 in 2025.
Across 176 payments — averaging $15.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$533
- AbbVie$434
- Lilly USA, LLC$327
- AstraZeneca$190
- Merck$130
- Biohaven Pharmaceutical Holding Company Ltd.$128
- plus $1K from 22 others
What the payments were for
- Food & beverage$2,782100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 37 | $533 |
| AbbVie | 32 | $434 |
| Lilly USA, LLC | 20 | $327 |
| AstraZeneca | 6 | $190 |
| Merck | 8 | $130 |
| Biohaven Pharmaceutical Holding Company Ltd. | 7 | $128 |
| GSK | 7 | $105 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 7 | $103 |
| Otsuka America Pharmaceutical, Inc. | 5 | $87 |
| Biohaven Pharmaceuticals, Inc. | 5 | $75 |
| Insulet Corporation | 4 | $69 |
| Boehringer Ingelheim | 4 | $67 |
| Eisai Inc. | 4 | $55 |
| Sanofi-aventis U.S. LLC | 4 | $55 |
| Currax Pharmaceuticals LLC | 4 | $51 |
| Astellas Pharma US Inc | 2 | $48 |
| Pfizer | 3 | $47 |
| Novartis | 2 | $42 |
| Johnson & Johnson | 2 | $37 |
| Bayer | 2 | $36 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $35 |
| Dexcom, Inc. | 2 | $34 |
| Lundbeck LLC | 1 | $21 |
| Medtronic | 1 | $19 |
| Inspire Medical Systems, Inc. | 1 | $19 |
| Avanir Pharmaceuticals, Inc. | 1 | $17 |
| Sanofi Pasteur Inc. | 1 | $14 |
| Genentech USA, Inc. | 2 | $9 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- BREZTRI$106
How this compares
$2,782 in reported general payments places this provider in the 80th percentile of 189 primary care providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 43 | $50,521 |
| FarxigaDapagliflozin Propanediol | 38 | $46,462 |
| OzempicSemaglutide | 27 | $41,195 |
| EliquisApixaban | 25 | $30,160 |
| MounjaroTirzepatide | 12 | $24,095 |
| TrulicityDulaglutide | 11 | $24,065 |
| VraylarCariprazine Hcl | 12 | $19,109 |
| RybelsusSemaglutide | 18 | $18,830 |
| JardianceEmpagliflozin | 12 | $16,643 |
| MyrbetriqMirabegron | 29 | $14,909 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 15 | $10,717 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 92 | $3,187 |
| Omeprazole | 79 | $1,600 |
| Atorvastatin Calcium | 93 | $1,243 |
| Losartan Potassium | 78 | $993 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaBreztri Aerosphere, Farxiga | $190 | $96,98381 claims |
| Novo NordiskOzempic, Rybelsus | $533 | $60,02545 claims |
| Lilly USA, LLCMounjaro, Trulicity, Humulin 70-30 | $327 | $48,72434 claims |
| PfizerEliquis | $47 | $30,16025 claims |
| AbbVieVraylar | $434 | $19,10912 claims |
| Boehringer IngelheimJardiance | $67 | $16,64312 claims |
| Astellas Pharma US IncMyrbetriq | $48 | $14,90929 claims |
| GSKTrelegy Ellipta | $105 | $10,71715 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 189 primary care providers in Tennessee.
Other primary care in Monteagle
- Ronald WintonMonteagle$3K
- Mary SullivanGermantown$115K
- Len GetzMemphis$25K
- Judith CaldwellNashville$18K
- Mara HutchingsNashville$14K
- Reena BhaktaMurfreesboro$12K
- Ryan HartmanNashville$11K
- Martha LemonsBrentwood$11K
- Abigail EubankHendersonville$9K
- Corey ClelandSevierville$9K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.